Literature DB >> 3777167

Stimulation of growth of a colon cancer cell line by gastrin.

C J Kusyk, N O McNiel, L R Johnson.   

Abstract

The trophic effects of the hormone gastrin-17 were examined on a human colon cancer cell line. LoVo cells were obtained from the American Type Culture Collection and grown in minimal essential medium in the presence of 10% bovine fetal serum. To demonstrate the trophic effect of gastrin, synchronization was necessary. The effect of gastrin was optimal after 26-h exposure to 0.6 mM thymidine. In the presence of serum the optimal dose of gastrin for stimulation of DNA synthesis was 7.2 X 10(-10) M. Under these conditions gastrin caused a 220% increase in [3H]thymidine incorporation. In the absence of serum the optimal dose of gastrin (3.6 X 10(-9) M) increased DNA synthesis approximately 200%. Twenty-four hours after gastrin treatment (1.8 X 10(-10) M gastrin 17) cell numbers increased 50.8% compared with control. At 48 h this increase was maintained at 44%. Maximum stimulation by gastrin occurred 7-8 h after release from synchronization and exposure to gastrin. This corresponded to the S phase of the cell cycle. Significant stimulation occurred a second time at 22-24 h, presumably during the second S phase in a still synchronous or partially synchronous cell population. These data demonstrate that physiological concentrations of gastrin-17 can stimulate the growth of a human cancer cell line and that some degree of synchronization may be necessary to demonstrate similar effects in other cell lines. Such cell lines may provide a source of rapidly growing cells in which the mechanisms of the trophic effect of gastrin can be examined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3777167     DOI: 10.1152/ajpgi.1986.251.5.G597

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  30 in total

1.  Gastrin, somatostatin, and experimental disturbance of the gastrointestinal tract in rats.

Authors:  Y L Yao; B Xu; W D Zhang; Y G Song
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

Review 2.  The risk of large bowel cancer after partial gastrectomy for benign ulcer disease.

Authors:  G Lundegårdh; H O Adami; C Helmick; M Zack
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

3.  Chemoprevention of esophageal adenocarcinoma.

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

4.  Synthesis and biological activity of 5-aza-ellipticine derivatives.

Authors:  Deborah L Moody; Marcin Dyba; Teresa Kosakowska-Cholody; Nadya I Tarasova; Christopher J Michejda
Journal:  Bioorg Med Chem Lett       Date:  2006-10-04       Impact factor: 2.823

5.  Elevated gastrin levels in patients with colon cancer or adenomatous polyps.

Authors:  J P Smith; J G Wood; T E Solomon
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

6.  Effect of gastrin and anti-gastrin antibodies on proliferation of hepatocyte cell lines.

Authors:  M Caplin; K Khan; S Grimes; D Michaeli; K Savage; R Pounder; A Dhillon
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

7.  Growth-promoting effects of gastrin on mouse colon cancer cells in vitro: absence of autocrine effects.

Authors:  Y S Guo; M Baijal; G F Jin; J C Thompson; C M Townsend; P Singh
Journal:  In Vitro Cell Dev Biol       Date:  1990-09

Review 8.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

9.  Human colon tumor cell line LS174T drug metabolizing system.

Authors:  D K Hammond; H W Strobel
Journal:  Mol Cell Biochem       Date:  1990-03-27       Impact factor: 3.396

10.  Peptide YY selectively stimulates expression of the colonocytic phenotype.

Authors:  S A Sgambati; G A Turowski; M D Basson
Journal:  J Gastrointest Surg       Date:  1997 Nov-Dec       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.